For more than 60 years, Bristol Myers Squibb has pioneered the science behind many of the game-changing advances in cardiovascular disease. As we have worked to bring forward new and transformative therapies for patients, our life-saving medicines have benefited millions of people around the world. We continue that work today. We are innovating next-generation medicines in areas of high unmet need such as arterial thrombosis, heart failure and cardiomyopathies. In late 2021, we announced promising research from AXIOMATIC-TKR, the first of two Phase 2 studies evaluating milvexian, our investigational oral factor XIa inhibitor (FXIa). AXIOMATIC-TKR is the first proof-of- principle study completed to demonstrate FXIa inhibition with a small-molecule drug has the potential to be an effective oral antithrombotic agent that does not increase risk of bleeding. Milvexian’s potential to be a safer oral anticoagulant could benefit a wider number of eligible patients who receive anticoagulation therapy–an important and promising advance.
Mavacamten is another important compound in our cardiovascular pipeline. Mavacamten is a potential first-in-class medicine targeting the underlying disease of symptomatic obstructive hypertrophic cardiomyopathy (HCM), a chronic heart disease that can potentially lead to debilitating symptoms and serious complications. HCM is a cardiovascular disease with serious unmet need, and we have ongoing clinical trials evaluating mavacamten’s potential ability to treat additional indications, including non-obstructive HCM.